A Phase I, Open-label Trial to Investigate the Metabolism, Pharmacokinetics (Following a Mass Balance Design; Part A) and Absolute Bioavailability of BI 1839100 (C-14) After Oral and Intravenous Administration (Part B) in Healthy Male Subjects
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs BI 1839100 (Primary) ; BI 1839100 (Primary)
- Indications Pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Dec 2024 Planned End Date changed from 2 Dec 2024 to 8 Oct 2025.
- 19 Dec 2024 Status changed from active, no longer recruiting to suspended.
- 02 Dec 2024 Status changed from recruiting to active, no longer recruiting.